INTRODUCTION
Accidental or belligerent radiation exposures may result in significant lung and renal injuries (1) . These will be especially important in subjects who have partial-body exposures that spare some bone marrow, thus averting death due to hematopoietic failure. We have established that angiotensin-converting enzyme inhibitors (ACEi) mitigate clinical radiation injury to lungs and to kidneys (2) . We use the term ''mitigate'' [as defined by the National Institutes of Health in 2004 (3) ] to refer to therapies begun after irradiation, but before there is physiological evidence of injury. Subjects who survive radiation-induced pneumonitis (typically at 1-3 months after irradiation) will be at risk for radiation-induced nephropathy in the weeks and months after the exposures (1). It is not known whether ACEi will mitigate both injuries when they occur sequentially. We sought to establish a model of dual-organ injury and its mitigation, in which lung injury occurs then followed by renal injury.
In previous studies using a total-body irradiation (TBI) rat model, we established that renal failure was the major cause of death at 100 days or more after 10 Gy single-fraction TBI in barrier-maintained rats that avoided hematopoietic lethality because of marrow transplantation (4) . In the same model, lung injury occurred 50-90 days after single-fraction radiation doses of 10 Gy or more (5, 6) . Gastrointestinal (GI) injury within the first ten days after irradiation was the cause of mortality for single-fraction TBI at doses greater than 13 Gy (4). We therefore used doses of 12.5, 12.75 and 13 Gy to establish a sequential GI-then-lung-then-kidney injury model in male rats, and to establish the dose modification factor (DMF) for enalapril in this model. Further, to model partial-body exposures as could occur for accidental or belligerent exposures, we shielded one hind limb of the irradiated rat, which enables auto-grafting of hematopoietic stem cells and eliminates death from hematopoietic failure. We tested the mitigation benefit of the ACEi enalapril in this model, and attempted to duplicate its expected clinical use by increasing the dose of enalapril when the irradiated rats developed hypertension.
Experimental Methods
The study was performed in syngeneic WAG/RijCmcr rats that were bred and housed in a moderate-security barrier. The animals were free of Mycoplasma pulmonis, Pseudomonas and common rat viruses. No antibiotics or immunosuppressive drugs were used. The rats were maintained in the Biomedical Resource Center of the Medical College of Wisconsin, which is fully accredited by the American Association of Accreditation of Laboratory Animal Care. The animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC).
Seventy-one WAG/RijCmcr 7-week-old male rats were irradiated with one hind limb shielded; we refer to this as a partial-body irradiation (PBI) model. Twenty-four rats underwent 12.5 Gy single-fraction PBI, 24 underwent 12.75 Gy single-fraction PBI and 23 underwent 13 Gy single-fraction PBI. The range of doses was used so that we could calculate a DMF for the ACEi treatment. Six normal rats were not irradiated and served as age-matched normal controls. Irradiation was performed with an X-RAD 320 KV orthovoltage X-ray system (Precision X-Ray, Branford, CT) operated at 320 kVp and 13 mAs with a half-value layer of 1.4 mm copper. During irradiation, each rat was confined in a separate chamber in a plastic jig, which allowed irradiation of 4 rats simultaneously. The radiation dosimetry was described in detail by Moulder et al. (7) .
Rats were followed to the endpoints of acute radiation syndrome (ARS; moribund prior to 30 days), of symptomatic pneumonitis [see Kma et al. (8) for IACUC-defined euthanasia criteria] or nephropathy [BUN . 120 mg/dl, also per IACUC (9)]. Two-thirds of the animals were given enalapril (at 30 mg/l in the drinking water) starting at day 5 after PBI; this is a nonhypotensive dose in rats, equivalent (on a mg/m 2 /day basis) to 30-40 mg/day in humans (which is the usual dose range in clinical use). The basis for choosing day 5 as the starting point of treatment is detailed in the Discussion section. The enalapril was pharmaceutical grade from Sigma Chemicals (St. Louis, MO). Blood urea nitrogen (BUN) was monitored serially and is an excellent marker of renal injury in this model (9) . Ten animals died from ARS at 5-17 days after PBI. When BUN rose to 30 mg/dl (1.53 normal) in an enalapril-treated group (at 10-14 weeks postirradiation depending on radiation dose), the surviving animals were stratified by BUN; half of the animals remained on 30 mg/l enalapril (the ''fixed-dose'' group) and the other half had their enalapril dose escalated to 60 mg/l (the ''escalateddose'' group). At 22-24 weeks after irradiation, the escalated-dose group (60 mg/l) were further escalated to 120 mg/l because their BUN was rising at the same rate as in the fixed-dose group (30 mg/l).
Statistics
Actuarial ''survival'' curves were created by the KaplanMeier method to show rat survival free from morbidity requiring euthanasia, and these curves were compared by log-rank tests. Fifty percent lethal doses (LD 50 , literally 50% morbidity requiring euthanasia) were calculated by probit analysis using the method of Finney (10) . DMFs were calculated by fitting parallel probit curves to the survival data (10); this procedure is described in more detail in Moulder et al. (9) . LD 50 and DMF are shown with 95% confidence intervals. BUN is shown as medians with 20-80% ranges.
RESULTS
Irradiated rats had morbidity requiring euthanasia in early, middle, and late phases (Fig. 1) . The first phase corresponds to ARS (most, if not all of which was due to GI rather than hematological injury), the second to lung injury and the third to renal injury. While there could be some overlap in time between the lung and renal morbidity, they can be distinguished in individual rats based on whether euthanasia was based on pneumonitis or nephropathy criteria. Enalapril had no effect on the early (ARS) phase, which is not unexpected because enalapril did not start until 5 days after PBI, and we have previously shown that ACEi do not mitigate GI (11) or hematological (12) radiation-induced injury in this model. Thereafter, both the enalapril fixeddose and the enalapril escalated-dose groups showed significant mitigation benefit compared to irradiated rats not receiving drug (Table 1) . Compared to the rats on the fixed dose of enalapril, escalating the enalapril dose did not significantly improve morbidity (P ¼ 0.19 by the log-rank test), although there is a trend favoring the escalated-dose schedule (Table 1 and Fig. 2) .
To evaluate the power of the study to detect changes in morbidity, DMFs were calculated ( Fig. 3 and Table 1 ). At 165 days after irradiation, the DMF for escalated-dose enalapril was 1.03 (1.00-1.06) compared to a fixed-dose enalapril. Thus while there may have been a slight FIG. 1. Actuarial survival (literally absence of morbidity requiring euthanasia) after partial-body irradiation (PBI) for rats receiving PBI only vs. rats receiving PBI plus an ACEi. PBI was given in a single dose at 12.5, 12.75 and 13.0 Gy (these dose groups are merged for this analysis). The ACEi, enalapril, was given in the drinking water (at 30 mg/l) starting on day 5 after PBI and continuing for the duration. Hatched areas show the cause of morbidity at different post-PBI times, and the number of animals at risk is shown in parentheses. The ACEi therapy caused a significant (P , 0.002) overall delay in morbidity.
advantage to escalating the dose, but it could not have been more than a 6% decrease in LD 50 , which would not be biologically significant. This evaluation was done at 165 days, as this was the median survival in the two groups, and the probit method for calculating DMFs is most powerful when overall survival is close to 50%; analyzing at significantly longer and shorter times yields nonsignificant differences in the DMF (because of the wide confidence intervals). To evaluate the overall effects of enalapril, the fixed-and escalated-dose groups were combined to yield a DMF of 1.06 (1.03-1.09) at 125 days. A shorter survival time was used for this calculation, as no animals that were not treated with enalapril were alive at 165 days. While the latter DMF is not impressive, we know that higher doses of enalapril, started immediately after irradiation are considerably more effective for mitigation of radiation-induced injury (7); however, these higher doses would probably not be considered acceptable for use in normotensive humans.
To separate the effects of the enalapril therapy on pneumonitis compared with nephropathy a survival analysis was done on animals that survived the ARS phase, but had to be euthanized for pneumonitis. This shows some mitigation efficacy for enalapril (90% survival with enalapril treatment vs. 76% survival with PBI alone, P ¼ 0.09); but it shows no difference between the fixed-and escalated-dose groups (P . 0.20).
To evaluate mitigation effects on nephropathy, we evaluated BUN at intervals after irradiation (Fig. 4) . Both the fixed-and escalated-dose enalapril groups showed significantly lower BUNs than animals receiving PBI alone at all times after the first ACEi dose escalation when the three dose groups are pooled (all P , 0.02); if the individual dose groups are not pooled, the number of pair-wise comparisons (n ¼ 24) overwhelms any attempt to analyze the statistical significance of differences. Enalapril doseescalation did not mitigate radiation-induced nephropathy to a significantly greater degree than did the fixed-dose enalapril regimen when the three dose groups are pooled (all P . 0.15 at 21-90 days), but there is a trend favoring the dose-escalation group at 120 days (P ¼ 0.06).
DISCUSSION
The mitigation of late radiation-induced injury from highdose partial-body irradiation is particularly relevant to accidental or belligerent exposures in which there will probably be uneven radiation exposures. Further, it is likely that any mitigating agent will be used initially in its lowest commonly used dose, and then dose escalated as indicated by the clinical features of the injured subject. Those features include the development of hypertension as part of renal Fig. 3 .
FIG. 2.
Actuarial survival (literally absence of morbidity requiring euthanasia) for rats given a fixed dose of ACEi vs. rats given an ACEi dose that was accelerated as the animals developed nephropathy. The analysis begins at the time of the first escalation (70-100 days post PBI), as there is no difference among the groups until that time. PBI are the same as those described for Fig. 1 . For the fixed-dose ACEi group (dashed line), enalapril, was given in the drinking water (at 30 mg/l) starting on day 5 after PBI and continuing for the duration (described in Fig. 1 ). For the accelerated-dose ACEi group (dotted line), ACEi dosing began the same way, but the dose was doubled when BUN reached 1.53 normal (70-100 days post PBI), and doubled again when BUN continued to progress (155-170 days post PBI). The difference in the incidence of morbidity is not statistically significant (P ¼ 0.19). radiation injury. The current studies confirm the benefit of enalapril to prolong survival of irradiated animals. They do not show a significant benefit of dose escalation of enalapril.
In a remnant kidney model of chronic renal failure, enalapril given at a dose of 50 mg/l in the drinking water stabilizes established renal injury (13) . The initial use of ACEi for treatment and mitigation of radiation nephropathy was based on that and on other studies showing the use of ACEi's to slow progression of experimental and clinical renal disease. Accordingly, Juncos et al. and we showed the benefit of enalapril at 50 mg/l in the drinking water to slow the progression of experimental radiation nephropathy (14, 15) . Even higher doses of enalapril, 200 mg/l, have been reported to cause regression of injury in the remnant kidney model (16) . But daily doses of enalapril in human use generally do not exceed 30 mg/day, in part because of the risk of side effects. The 30 mg/l dose of enalapril fixed-dose study overlaps (on a g/m 2 /day basis) with a 30-40 mg/day dose in humans, which is the usual dose range of its clinical use. The 120 mg/l concentration of enalapril in the drinking water (the escalated-dose arm in the current study) would be equivalent to as much as a 120-150 mg/day human dose, which is well in excess of recommended human doses. Nonetheless, some clinical evidence favors higher, rather than lower doses of enalapril. The dose of enalapril was 2.5-20 mg/day in a major study that showed its benefit in heart failure (17) . A more recent study of its use in heart failure showed a trend towards greater benefit for dose of 40 mg/day compared to 5 mg/day (18) . It was therefore necessary to test higher doses of enalapril in a combined injury partial-body irradiation model.
We have previously shown that higher doses of the ACEi captopril are more effective than lower doses in preventing experimental radiation nephropathy [i.e., when started before irradiation and continued continuously thereafter (19) ]. In addition, after 13 Gy whole-thorax irradiation, . PBI are the same as those described for Fig. 1 and enalapril (ACEi) schedules are the same as those described in Fig. 2 . In panel A, dose-response curves are shown for PBI only and PBI plus both ACEi schedules; the difference between ACEi and no ACEi is statistically significant (Table 1 ) . In panel B, dose-response curves are shown for each of the ACEi dose schedules; the difference between the two ACEi schedules is statistically significant, but very small (Table 1) .
FIG. 4.
Blood urea nitrogen (BUN) levels after PBI for rats given PBI alone ( ) or PBI plus a fixed dose of ACEi ( n ) or PBI plus accelerated doses of ACEi (u). The analysis begins at the time of the first escalation (70-100 days post PBI), as there is no difference among the groups until that time. PBI are the same as those described for Fig. 1 . The ACEi dose schedules are the same as those described in Figs. 2 and 3 . BUN values for PBI alone are significantly higher (P 0.005) than for both ACEi schedules at all times more than 30 days after the first escalation. Data are shown as medians with 20-80% ranges; BUNs were arbitrarily set at 300 mg/l for animals that had to be euthanized because of high BUN. Both enalapril groups showed significantly lower BUNs than animals receiving PBI only (all P, 0.02). Enalapril dose-escalation did not significantly lower BUNs (all P . 0.15 at 21-90 days and P ¼ 0.06 at 120 days vs. the fixed dose enalapril regimen).
enalapril doses of 18-36 mg/m 2 exert increasing benefit as a mitigator of pulmonary injury (20) . But when used to treat established radiation nephropathy, low-dose captopril has the same benefit as does the highest dose (21) . The results of the current study are consistent with that, because dose escalation of enalapril in rats with developing radiation nephropathy, corresponding to use in treatment, did not yield greater benefit for mitigation of renal injury. We speculate that this is because the active enalapril metabolite, enalaprilat, is renally excreted; and thus when enalapril is used in treatment of established kidney disease, the plasma levels of enalaprilat may rise as the kidney function declines, even when using a fixed dose.
The mechanism of the therapeutic benefit of enalapril is probably via its known effect to inhibit ACE. Human doses of enalapril of 40 mg/day yield active enalaprilat plasma levels of ;0.1 lmol/L (22). These plasma levels will inhibit ACE activity (23) . Even lower enalaprilat plasma levels may be effective in subjects treated with oral enalapril for chronic kidney disease (24) . On the other hand, enalaprilat levels near the millimolar range are needed to exert antioxidant effects in vitro (25) . The 30 mg/L enalapril dose used in the current fixed-dose study has a significant effect on the renin-angiotensin system (7) and had an antihypertensive effect; but it does not appear to be able to achieve enalaprilat levels in the millimolar range that would support an action as an anti-oxidant.
The decision to start treatment on day 5 was based on multiple considerations. First, because ACE inhibitors have no significant effect on the hematopoietic injury phase in rats (12) the hematopoietic system would not benefit from an earlier start. Second, ACE inhibitors may exacerbate radiation-induced gastrointestinal injury (26) , so delaying the start of therapy until after the peak of acute gastrointestinal would be clinically appropriate. Finally, we are attempting to model a realistic scenario for accidental or belligerent radiation exposure where therapies could not be started immediately and probably would not be started until after preliminary dose estimation and triage (1) .
The current model is one of sequential and overlapping normal tissue injuries, as could occur after accidental or belligerent exposures. These are the early injuries to the GI tract (and possibly the hematopoietic system) within the first 13 days, then the lung injury as pneumonitis between 40 and 90 days after irradiation, followed by the renal injury manifesting from 100 days onward. A similar sequence occurs in non-human primates after 10-13 Gy PBI with the leg bone marrow shielded to avoid hematopoietic death (27) . Use of ACEi as a mitigator could thus be applied to subjects who had survived the early hematopoietic phase (e.g., because of partial-body shielding) and who had survived the GI phase (e.g., with supportive care such as antibiotics and intravenous fluids). The current data support use of the ACEi enalapril at a fixed and clinically usable dose to mitigate radiation injury after partial-body irradiation.
